Adding to This Semi-Cap Equipment Holding After Connecting the Dots
We are also lifting our rating on the shares.
We are also lifting our rating on the shares.
Qatar’s diplomatic efforts, Warsh on deck and other headlines moving the market this morning.
Robust demand for Nvidia products continues, but someone is paying a hefty price.
Nvidia’s results beat Wall Street expectations by a mile, signaling the AI trade is alive and well.
Here are yesterday’s things:
* I covered $NVDA at $206.60 and re-shorted at $218.50.
* I added to my $CRVW short at $90.79.
* I added to two ETF shorts — $GRNY at $27.88 and $JOET at $46.19.
* I added to my $JPM short at $356.80.
* I shorted $SPY at $769.29 and covered at $768.53.
* I shorted $QQQ at $716.73 and covered at $715.02.
Position: Short NVDA (VS), CRVW (VS), GRNY (M), JOET (S)
The stock is trading lower after the bell but the big question is how it impacts the broader market.
That was a long, tough day. All of that macroeconomic data did nothing to spark the marketplace. We had to wait until the closing bell to see some of the type of action we, as traders, crave.
Equities closed slightly lower on Wednesday as traders awaited Nvidia’s ($NVDA) results, among others. The S&P 500 ended almost flat at -0.02%, while the Nasdaq Composite gave back -0.08%. Can’t make that stuff up.
Five of the 11 S&P sector SPDR ETFs wound up in the green, led by industrials ($XLI). Health Care ($XLV) was the weakest performer among these funds.
Treasury yields climbed. The U.S. 2-Year Treasury yield moved up 3 basis points to 4.21%, while the U.S. 10-Year Note paid 4.65% (+3 bps) by day’s end. The yield on the U.S. 30-Year Treasury yield ticked up 1 basis point to 5.17%.
As I send this note, we are still waiting on Nvidia. CrowdStrike ($CRWD), Okta ($OKTA) and Salesforce ($CRM) have all already reported. The market has react favorably to all three.
Position: Long NVDA, CRWD equity
We’re waiting on Nvidia as chip competition intensifies.
As retailers get hit and AI-plays bubble over, I’ve got my sights on these two promising biopharma stocks.
As we get big news from the Meta case and await Nvidia earnings, here’s a company I’m adding to my shopping list.